PMID: 11337186May 5, 2001Paper

Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae

Diagnostic Microbiology and Infectious Disease
G E Stein, Sharon Schooley

Abstract

The serum pharmacodynamics of clarithromycin and azithromycin were studied against isolates of S. pneumoniae, including efflux resistant (M. phenotype) strains, by analyzing their serum bactericidal activity (SBA) over time. Normal healthy subjects were given a single 500 mg oral dose of these macrolides and serum samples were collected over 12 hrs. Paired isolates with MICs ranging from 0.25 ug/ml to 8.0 ug/ml were analyzed. Prolonged (at least 6 hrs) SBA was observed with clarithromycin for strains with MICs < or = 2.0 ug/ml. No SBA was observed in strains with MICs >or = 4.0 ug/ml. Azithromycin exhibited SBA for at least 6 hrs for strains up to a MIC = 0.5 ug/ml. No SBA was observed for isolates with MICs > or = 1.0 ug/ml. In contrast to azithromycin, clarithromycin exhibited SBA for at least one-half of its normal dosing interval against S. pneumoniae strains well above its current susceptibility breakpoint concentration of 0.25 microg/ml. These findings may have relevance to the ongoing debate as to the appropriate susceptibility breakpoints for the newer macrolides.

References

Jun 1, 1992·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·M S Whitman, A R Tunkel
Mar 1, 1992·Diagnostic Microbiology and Infectious Disease·W W HooverR N Jones
Oct 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H Lode
Oct 1, 1988·Antimicrobial Agents and Chemotherapy·B J Guglielmo, L C Rodondi
Nov 1, 1988·Antimicrobial Agents and Chemotherapy·D J HardyP B Fernandes
Apr 11, 1985·The New England Journal of Medicine·J S Wolfson, M N Swartz
Mar 1, 1982·Reviews of Infectious Diseases·G M Eliopoulos, R C Moellering
Jun 1, 1993·The Journal of Antimicrobial Chemotherapy·G PanteixM Perrin-Fayolle
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Jul 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C Carbon
Feb 13, 1999·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·A CorsoA Tomasz
Aug 25, 1999·The Journal of Antimicrobial Chemotherapy·G W Amsden
Aug 30, 2000·Clinical Therapeutics·J M McCarty
Oct 26, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M A KelleyM S Cohen
Jun 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E J Baron
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·Pamela R TessierDavid P Nicolau
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN Infectious Diseases Society of America
Dec 9, 2003·International Journal of Antimicrobial Agents·Sofia IoannidouAlkiviadis C Vatopoulos

❮ Previous
Next ❯

Citations

Jul 1, 2004·International Journal of Antimicrobial Agents·Antonio Anzueto, Sandra Norris
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Malcolm J M Darkes, Caroline M Perry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.